Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epo-alpha · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Epo-alpha | DRUG | - |
Inclusion Criteria: * Patients who have OHCA of presumed cardiac origin * Patient's who have delay between the collapse and onset of cardiopulmonary resuscitation (CPR, no flow) less that 10 minutes * Patient's who have delay between onset of CPR and return of spontaneous circulation (ROSC, low flo...
Epo-alpha is being studied for use in resuscitation, specifically in the setting of cardiac arrest. It is an investigational small molecule being developed by Johnson & Johnson (JNJ) for this cardiovascular indication. The drug is currently in Phase 3 clinical development.
Epo-alpha is being developed by Johnson & Johnson, which trades under the ticker JNJ. The company is conducting clinical trials to evaluate the drug for use in resuscitation, particularly in cases of cardiac arrest. Epo-alpha is currently in Phase 3 development.
Epo-alpha is in Phase 3 clinical development. It is being studied for use in resuscitation, specifically for patients experiencing cardiac arrest. The drug is investigational and has not yet been approved by regulatory authorities. Johnson & Johnson (JNJ) is the developer.
Epo-alpha has one completed clinical trial, identified as NCT00719498, titled "Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)." This Phase 3 trial enrolled 20 participants and was not randomized or double-blinded. The study focused on resuscitation and cardiac arrest conditions.
Yes, Epo-alpha is also known as Epoetin Alfa. The clinical trial NCT00719498, which studied the drug for cardiac arrest resuscitation, uses the name Epoetin Alfa in its title. The drug is being developed by Johnson & Johnson (JNJ) for this cardiovascular indication.